Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Fremanezumab (TEV-48125) Expanded Access Program for Patients With Migraine

Trial Profile

A Fremanezumab (TEV-48125) Expanded Access Program for Patients With Migraine

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 16 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
  • Most Recent Events

    • 13 Jul 2020 Status changed from suspended to completed.
    • 16 Apr 2020 Status changed from recruiting to suspended.
    • 31 May 2018 New trial record
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top